Masahiro Sakane - Takeda Pharmaceutical Independent Director
| TKPHF Stock | USD 25.77 0.75 2.83% |
Director
Mr. Masahiro Sakane was serving as Independent Chairman of the Executive Board in Takeda Pharmaceutical Company Limited since June 2017. He is also serving as Independent Director in KAJIMA CORPORATION, and working for Komatsu Ltd. since 2017.
| Age | 77 |
| Tenure | 7 years |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Noritaka Uji | Daiichi Sankyo | 68 | |
| Hideki Shima | Astellas Pharma | N/A | |
| Yuki Sato | Daiichi Sankyo | 64 | |
| Yasuo Ikeda | Chugai Pharmaceutical Co | 74 | |
| Masahiro Ohtsuki | Daiichi Sankyo | N/A | |
| Tsunanori Sato | Chugai Pharmaceutical Co | N/A | |
| Takuya Oshida | Astellas Pharma | N/A | |
| Noriyuki Uematsu | Astellas Pharma | 57 | |
| Kohei Wada | Daiichi Sankyo | N/A | |
| Yoshiharu Aizawa | Astellas Pharma | 71 | |
| Hisanori Takanashi | Chugai Pharmaceutical Co | N/A | |
| Hitoshi Kuboniwa | Chugai Pharmaceutical Co | N/A | |
| Naoki Adachi | Daiichi Sankyo | 79 | |
| Katsumi Fujimoto | Daiichi Sankyo | 62 | |
| Takahisa Iizuka | Astellas Pharma | N/A | |
| Christoph Franz | Chugai Pharmaceutical Co | 58 | |
| Hiroshi Murata | Chugai Pharmaceutical Co | N/A | |
| Hitoshi Kanamori | Astellas Pharma | 63 | |
| Chihiro Yokota | Astellas Pharma | N/A | |
| Hiroshi Hirabayashi | Daiichi Sankyo | 74 | |
| Minoru Watanabe | Chugai Pharmaceutical Co | N/A | |
Management Performance
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rudolf Houten, Acting CFO and Group Financial Controller | ||
| Constantine Saroukos, CFO Director | ||
| Christophe Weber, CEO and President and Representative Director | ||
| Masahiro Sakane, Independent Director | ||
| Seigo Izumo, Chair Board | ||
| Gabriele Ricci, Chief Officer | ||
| Fumio Sudo, Independent Director | ||
| Yorihiko Kojima, Independent Director | ||
| JeanLuc Butel, Independent Director | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Sr Department | ||
| Michel Orsinger, Independent Director | ||
| Shiro Kuniya, Independent Director | ||
| Emiko Azuma, Independent Director | ||
| Christopher OReilly, Global Fin | ||
| Shinji Honda, Sr. Managing Director, Sr. VP, Corporate Strategy Officer and Director | ||
| Toshiyuki Shiga, Independent Director | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller | ||
| Masato Iwasaki, Chief Director of Pharmaceutical Sales, Director | ||
| Yasuhiko Yamanaka, Managing Director of Special Missions and Director | ||
| Andrew Plump, Chief Medical and Scientific Officer and Corporate Officer | ||
| Tokumasa Takeda, IR Contact Officer | ||
| Yoshiaki Fujimori, Independent Director | ||
| Koji Hatsukawa, Independent Director | ||
| Yasuchika Hasegawa, Chairman and CEO |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 75.53 B | |||
| Shares Outstanding | 1.56 B | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 41.35 % | |||
| Price To Earning | 27.54 X | |||
| Price To Book | 0.97 X |
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Takeda Pink Sheet analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |